Toward improved outcomes in patients with anaplastic thyroid cancer

Oncology

Volumn 26, Issue 4, 2012, Pages

  Bible, Keith C ^a   Foote, Robert L ^a   Smallridge, Robert C ^b,c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PAZOPANIB; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ANAPLASTIC THYROID CANCER; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; EARLY INTERVENTION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; METASTASIS POTENTIAL; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PROGNOSIS; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 84860148924     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid. 2011;21:1183-1189.
2. Ito KI, Hanamura T, Murayama K, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: Improved survival in subgroups of patients with localized primary tumors. Head Neck. 2012;34:230-237.
3. Passler C, Scheuba C, Prager G, et al. Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg. 1999;384:284-293.
4. Swaak-Kragten AT, de Wilt JH, Schmitz PI, et al. Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol. 2009;92:100-104.
5. Pierie JP, Muzikansky A, Gaz RD, et al. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol. 2002;9:57-64.
6. Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91:2335-2342.
7. Kihara M, Miyauchi A, Yamauchi A, Yokomise H. Prognostic factors of anaplastic thyroid carcinoma. Surg Today. 2004;34:394-398.
8. Smallridge RC, Abate E. Anaplastic thyroid carcinoma: prognosis. In: Wartofsky L, Van Nostrand D, editors. Thyroid cancer: a comprehensive guide to clinical management. 3rd ed. New York: Springer; 2012 (In Press).
9. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000;10:587-594.
10. Kawada K, Kitagawa K, Kamei S, et al. The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol. 2010;40:596-599.
11. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62:3408-3416.
12. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19:233-240.
13. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155-2160.
14. Bonner JA, Lawrence TS. Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Biol. 1990;57:55-64.
15. Durand RE. Adriamycin: a possible indirect radiosensitizer of hypoxic tumor cells. Radiology. 1976;19:217-222.
16. Nabell L, Spencer S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol. 2003;30:89-93.
17. Niero A, Emiliani E, Monti G, et al. Paclitaxel and radiotherapy: sequence-dependent efficacya preclinical model. Clin Cancer Res.1999;5:2213-2222.
18. Kim JH, Leeper RD. Combination adriamycin and radiation therapy for locally advanced carcinoma of the thyroid gland. Int J Radiat Oncol Biol Phys.1983;9:565-567.
19. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 1987;60:2372-2375.
20. Tennvall J, Tallroth E, El Hassan A, et al. Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncologica. 1990;29:1025-1028.
21. Tennvall J, Lundell G, Hallquist A, et al. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Cancer. 1994;74:1348-1354.
22. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86:1848-1853.
23. Chen J, Tward JD, Shrieve DC, Hitchcock YJ. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma. Am J Clin Oncol. 2008;31:460-464.
24. Swaak-Kragten AT, de Wilt JH, Schmitz PI, et al. Multimodality treatment for anaplastic thyroid carcinomatreatment outcome in 75 patients. Radiother Oncol. 2009;92:100-104.
25. Pudney D, Lau H, Ruether JD, Falck V. Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid. 2007;17:1243-1250.
26. Higashiyama T, Ito Y, Hirokawa M, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010;20:7-14.
27. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21:25-30.
28. Sosa JA, Elisei R, Jarzab B, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial. J Clin Oncol. 2011;29(suppl; abstr 5502).
29. Harris PJ, Bible KC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs. 2011;20:1357-1375.